
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
MMS Holdings (MMS), a data-focused CRO, is offering a $1 million award toward the development of a vaccine for COVID-19. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or with other global health authorities. Organizations interested in applying for this award can submit a notification of interest at
For more information, click






